Hence, by endowing CAR T-cells with ADCC activity via the Fc-gamma receptor IIIa (CD16), they exhibit sustained proliferation and cytotoxicity to antibody-targeted cancer cells (228). This evidence concerns the gene FCGR3A and cancer.